How Accurate Are Blood Tests for Colon Cancer?

Blood tests for colon cancer have reached the point where they can detect confirmed cancers with roughly 80 to 93 percent sensitivity, depending on the specific test, while correctly ruling out cancer in about 90 percent or more of people who do not have it. That sounds promising, and it is, but the headline numbers obscure a critical gap: these tests are far less reliable at catching the precancerous growths that screening is ultimately meant to find. The full picture of accuracy depends on what you are hoping the test will catch and which alternative you would have used instead.

What the Largest Clinical Trial Actually Found

The most rigorous evidence so far comes from a large validation study of a circulating tumor DNA blood test, published in JAMA in 2025. The test detected colorectal cancer with a sensitivity of about 79 percent and a specificity for advanced colorectal neoplasia of roughly 92 percent. In plain terms, it correctly flagged about four out of five people who had cancer, and it correctly cleared about nine out of ten people who did not have advanced disease. The negative predictive value was around 91 percent, meaning that if the test came back negative, there was about a 91 percent chance you truly did not have advanced neoplasia.¹

A separate study reported even higher numbers for a different ctDNA-based multimodal assay, with 93 percent sensitivity and 90 percent specificity for detecting colorectal cancer.² The variation between these two results reflects differences in test design, study populations, and the stage distribution of cancers in each trial. In general, blood tests are better at finding cancers that are already established than catching disease at its earliest or pre-malignant stages.

The Precancerous Lesion Problem

This is where the story gets complicated, and where the gap between blood tests and traditional screening methods is widest. The same large JAMA trial that reported 79 percent sensitivity for cancer found only about 13 percent sensitivity for advanced precancerous lesions. That number did not meet the study’s own prespecified acceptance criterion.¹ Advanced precancerous lesions, often called advanced adenomas, are the growths that colonoscopy is specifically designed to find and remove before they ever become cancer. If a screening test misses nearly nine out of ten of them, it cannot do the same preventive job that colonoscopy does.

This is not a minor limitation. The entire rationale for colon cancer screening rests on catching growths early, ideally before they turn malignant. A test that reliably finds cancer but misses the precursors is useful, but it shifts the goal from prevention to early detection. Those are meaningfully different outcomes for a patient. Early detection still improves survival, but prevention through polyp removal avoids cancer altogether.

A cost-effectiveness analysis in the Journal of the National Cancer Institute put a number on what it would take for blood tests to compete: they would need advanced adenoma sensitivity above 40 percent and costs below $125 per test to be considered cost-effective alternatives to colonoscopy or stool-based tests.³ Current tests fall well short of that 40 percent threshold.

How Blood Tests Stack Up Against Colonoscopy and Stool Tests

Colonoscopy remains the gold standard because it both detects and removes suspicious growths in a single procedure. Annual stool-based tests and multi-target stool DNA tests occupy a middle ground: they are less invasive than colonoscopy but catch more precancerous lesions than blood tests do. A comparative effectiveness study modeled the long-term outcomes and found that blood tests meeting minimum coverage requirements reduced colon cancer incidence by about 40 percent and mortality by roughly 52 percent compared to no screening at all. Those are real benefits. But colonoscopy every ten years, annual stool immunochemical testing, and multi-target stool DNA testing every three years each reduced incidence by 68 to 79 percent and mortality by 73 to 81 percent.⁴

That gap matters. If you are someone who would otherwise get a colonoscopy on schedule, switching to a blood test means accepting meaningfully less protection. The same cost-effectiveness analysis that set the 40 percent adenoma sensitivity bar was blunt in its conclusion: blood tests that only meet minimum coverage requirements should not be recommended to patients who would otherwise screen by colonoscopy or stool testing, because the benefit is lower.³

This does not mean blood tests are pointless. It means they occupy a specific niche, and understanding that niche matters for making a good decision about your own screening.

Where Blood Tests Make the Strongest Case

About a third of Americans who are due for colon cancer screening are not up to date. The reasons are familiar: colonoscopy requires bowel prep, sedation, and a day off work. Stool tests require handling a sample at home, which some people find unpleasant enough to skip. A blood draw during a routine office visit removes most of those barriers. One real-world implementation study of a blood-based screening test found that among the first 20,000 patients offered the test, about 95 percent provided a sample, with short turnaround times for results.⁵

That adherence number is striking, though it comes with caveats. A systematic review of adherence to recommended blood-based screening tests more broadly found that real-world adherence is often suboptimal, and the reviewers flagged that it remains unclear whether the high initial uptake seen in some implementations will translate to sustained screening over time.⁶ Getting 95 percent of people to give a single blood sample is encouraging, but screening only works if people do it repeatedly on schedule. Whether blood tests maintain that high uptake over years of repeated screening rounds is still an open question.

The strongest argument for blood tests is not that they are as accurate as colonoscopy but that a less accurate test that people actually complete is better than a perfect test that sits on the to-do list indefinitely. For someone who has been avoiding screening entirely, a blood test that catches roughly 80 percent of cancers is vastly better than no screening at all.

How the Underlying Technology Works

Most current blood tests for colon cancer rely on detecting fragments of DNA that tumors shed into the bloodstream, known as circulating tumor DNA. Tumors leave a chemical fingerprint on this DNA through a process called methylation, where small chemical tags are added to specific spots along the DNA strand. The pattern of these tags differs between cancerous and healthy cells, and the tests use algorithms trained on large datasets to recognize those cancer-specific patterns.

One research group developed a model based on 11 methylation biomarkers that achieved strong accuracy in both a training group and a separate validation group, with consistent performance for early-stage cancers and advanced precancerous lesions alike.⁷ Another team screened over 193,000 potential methylation sites and used machine learning to narrow the field to 149 hypermethylated markers, constructing a model they call ColonSecure.⁸ The principle is the same across these approaches: scan blood for tumor-derived DNA fragments and look for patterns that healthy tissue does not produce.

The reason precancerous lesions are so much harder to detect is that they shed far less DNA into the bloodstream than established cancers do. A small polyp that has not yet invaded surrounding tissue releases only tiny amounts of circulating DNA, sometimes too little for even a sensitive assay to reliably pick up. Larger, more advanced tumors push more DNA into circulation, which is why sensitivity climbs with cancer stage.

Newer Approaches Pushing Accuracy Higher

Researchers are not standing still on the precancerous-lesion gap. One of the more promising strategies is combining multiple types of biological signals rather than relying on DNA methylation alone. A 2024 study tested a multiomics approach that integrated several different genomic features from a single blood sample and achieved notably high accuracy in validation testing, with sensitivity of about 92 percent and specificity around 95 percent. The stage-by-stage performance was particularly interesting: 80 percent sensitivity for stage I cancers, about 89 percent for stage II, and 100 percent for stages III and IV.⁹

Those are impressive numbers, and the fact that even stage I sensitivity reached 80 percent in this particular study is a meaningful advance. But these results came from a research setting with carefully selected cohorts, not from mass screening of average-risk adults. Validation studies in more diverse, real-world populations will determine whether the performance holds up. There is a long track record in cancer diagnostics of tests that look outstanding in controlled studies and then lose accuracy when deployed at scale, where the population being tested is overwhelmingly healthy and the cancers being sought are rare.

Multi-Cancer Detection Tests and Colon Cancer

A related but distinct category of blood test aims to detect not just colon cancer but dozens of cancer types from a single blood draw. These multi-cancer early detection tests analyze methylation patterns across a vast number of sites and use machine learning to identify whether a cancer signal is present and, if so, where in the body it likely originated. An early validation study found that one such test achieved about 69 percent sensitivity across multiple cancer types with roughly 99 percent specificity, and it predicted the tissue of origin correctly in about 83 percent of true positive cases.¹⁰

For colon cancer specifically, these multi-cancer tests face the same fundamental challenge as dedicated colon cancer blood tests: they are better at finding established disease than precancerous growths. Their value lies more in catching cancers that currently have no routine screening method, like pancreatic or ovarian cancer. For colon cancer, where effective screening already exists, a multi-cancer test is more of a supplement than a replacement. If you rely solely on a multi-cancer test for colon cancer screening, you are likely giving up some of the protection that dedicated colon screening provides.

What a Positive Result Actually Means

One number from the JAMA trial deserves special attention: the positive predictive value for advanced colorectal neoplasia was only about 16 percent.¹ That means if you got a positive result, there was roughly a one-in-six chance you actually had advanced disease. The other five out of six positive results were false alarms. This is not unique to blood tests; any screening test applied to a large, mostly healthy population generates many false positives simply because the disease is uncommon relative to the number of people tested. But it does mean that a positive blood test is the beginning of a diagnostic workup, not a cancer diagnosis.

A positive result on a blood-based screening test leads to a follow-up colonoscopy. The blood test does not replace colonoscopy; it helps decide who should get one sooner. If the follow-up colonoscopy finds nothing, you are in the same position as someone who got a false-positive result on a stool test.

The Psychological Side of False Positives

Getting a positive screening result and then learning it was a false alarm is not a zero-cost experience. Studies on stool-based screening have documented what happens psychologically. In one study, people who received a false-positive stool test result had higher situational anxiety immediately afterward, though the anxiety was not at clinically significant levels and it faded within a few months.¹¹ Another study found that psychological distress decreased significantly after participants received their colonoscopy results showing no cancer, though about 17 percent of those with false-positive results still reported elevated cancer worry six months later. Regret about participating in screening was low overall, with only about 5 percent reporting high levels of regret.¹²

These findings come from stool test studies rather than blood test studies specifically, but the psychological dynamics are likely similar: a positive result triggers worry, the worry resolves for most people after a clear colonoscopy, and a small but real minority carries lingering anxiety. Blood tests may generate a somewhat different emotional experience since a blood draw feels more “medical” than a stool sample, but no published data yet distinguish the psychological responses by test type. If you receive a positive blood test result, knowing that false positives are common and that the colonoscopy follow-up is the definitive step can help keep the waiting period in perspective.

Who Should Consider a Blood Test Over Other Options

The clearest candidates are people who are eligible for colon cancer screening but have consistently declined or avoided colonoscopy and stool-based testing. For them, any screening is a dramatic improvement over none, and the convenience of a blood draw during a routine visit may be the factor that tips them from unscreened to screened. The 40 percent reduction in cancer incidence and 52 percent reduction in mortality compared to no screening are real, life-saving benefits.⁴

People who are already screening regularly with colonoscopy or stool tests should not switch to a blood test expecting equivalent protection. The evidence consistently shows that blood tests, at their current level of accuracy, provide less cancer prevention than the established methods. If you are comfortable with your current screening method and have been keeping up with it, there is no accuracy-based reason to change.

People with average risk who have never been screened and are now past age 45 might find a blood test to be a reasonable entry point into the screening system, especially if the result prompts a colonoscopy they would not otherwise have gotten. The test’s value in that scenario is less about its standalone accuracy and more about its role as a gateway to the diagnostic workup that follows.

One group for whom the data is still thin is people at elevated risk due to family history, inflammatory bowel disease, or prior polyps. These individuals typically need more aggressive surveillance, and whether a blood test adds anything meaningful on top of their already-scheduled colonoscopies has not been well studied. For higher-risk patients, colonoscopy remains the recommended approach regardless of what blood tests can offer.